Ozoralizumab shows effectiveness regardless of baseline RF and anti-citrullinated peptide antibody (ACPA) titres in patients with RA: a post hoc analysis of the OHZORA trial
Authors' conclusion
OZR is an effective anti-TNF treatment for RA, regardless of RF and ACPA titres
Study context
- Population
- Japanese patients with RA with inadequate response to MTX, treated with 30 or 80 mg ozoralizumab (OZR) over 52 weeks
- Participants
- 381 patients
- Comparison
- OZR efficacy across baseline RF and ACPA titre quartile groups
- Primary endpoint
- Efficacy of OZR (disease activity scores) in patients with RA in varying RF and ACPA titres
Methodological detailsPhase II/III
- Phase II/III
Primary result
As reported in the abstract
Disease activity, OZR 30 mg, across baseline RF/ACPA quartile groups
- OZR 30 mg significantly reduced disease activity in all the groups
- P < 0.001
Secondary outcomes
Mean RF titre, baseline to after OZR 30 mg
- Mean RF titre decreased from 149.5 to 71.1 IU/ml
- P < 0.001
Mean ACPA titre, baseline to after OZR 30 mg
- Mean ACPA titre decreased from 299.6 to 237.6 U/ml
- P < 0.001
OZR trough concentrations · up to 52 weeks
- Effective trough concentrations maintained for up to 52 weeks in all the groups
OZR-neutralizing antibodies
- Baseline RF and ACPA titres not associated with generation of OZR-neutralizing antibodies
Original publication
Ozoralizumab shows effectiveness regardless of baseline RF and ACPA titres in patients with RA: a post hoc analysis of the OHZORA trial. Rheumatology (Oxford). Published 26 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →